Bayer strategically and operationally successful

Group sales advance by 3.5 percent (Fx & portfolio adj.) to 43.545 billion euros / EBITDA before special items increases by 28.3 percent to 11.503 billion euros / Core earnings per share up by 14.3 percent to 6.40 euros / Net income rises 141.4 percent to 4.091 billion euros – gain of 1.637 billion euros on sale of Currenta stake / Free cash flow of 4.214 billion euros above expectations / Proposed dividend of 2.80 euros per share / Crop Science shows solid performance in challenging environment, substantial increase in earnings due to acquired business / Pharmaceuticals shows encouraging business development / Sales growth at Consumer Health, earnings at prior-year level despite divestments / Ongoing portfolio, structural and efficiency measures implemented successfully / Glyphosate’s positive safety profile confirmed – appeal and mediation proceedings moving forward / Outlook for 2020: increase in sales, earnings and free cash flow / Ambitious sustainability targets set

Address by Werner Baumann

Chairman of the Board of Management

Address by Wolfgang Nickl

Member of the Board of Management

On-demand video recording of the Financial News Conference with the speeches given by Werner Baumann and Wolfgang Nickl, and the subsequent Q&A session